Elucidation of pathophysiological significance of LIF and development of new treatment strategy in prostate cancer
阐明 LIF 的病理生理学意义并开发前列腺癌新治疗策略
基本信息
- 批准号:14571522
- 负责人:
- 金额:$ 2.11万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2002
- 资助国家:日本
- 起止时间:2002 至 2004
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
In vitro culture of JCA-1 cells produced a time dependent increase in medium levels of leukemia inhibitory factor (LIF). An NFkappaB inhibitor produced an inhibitory effect on LIF production in JCA cells. On the other hand, recombinant LIF demonstrated no significant effects on cell growth in prostate cancer cell lines, PC3, DU145 and JCA-1 cells. Serum levels of LIF in nude mice having JCA-1 tumors and PC3 tumors were increased, respectively, whereas those in control nude mice without tumors were not detected. At the same time, JCA-1 tumor-bearing mice produced a decrease in body weight 28 days after inoculation, although mice without tumors showed an increase in body weight. In vitro culture of JCA-1 cells also produces IL-6. Serum levels of IL-6 were also significantly elevated in JCA-1 tumor bearing nude mice accompanied with a loss of body weight when compared with control mice without tumors. Then, serum levels of LIF and IL-6 were measured in patients with prostate cancer. Serum … More levels of LIF were not detected in a majority of untreated patients and patients with progression after endocrine therapy. On the other hand, serum IL-6 levels were significantly elevated in untreated patients with stage D disease when compared with stage A, B and C patients. Serum IL-6 levels further increased in patients with progression after endocrine therapy. The serum total protein and albumin levels, hemoglobin levels, and body mass index of the patients with higher serum IL-6 levels were significantly lower than the corresponding values in patients with lower serum IL-6 levels. Significant correlation between serum IL-6 and serum albumin levels, hemoglobin levels, body mass index and performance status was found. An NFkappaB inhibitor produced statistically significant increase in body weight, epididymal fat and gastrocnemius muscle weight in JCA-1 tumor bearing nude mice, when compared to control mice. Hematocrit, serum albumin and triglyceride levels were significantly higher and serum IL-6 levels were significantly lower in treated mice than control mice. These results suggest that serum IL-6 may be associated with cachexia and an NFkappaB inhibitor may prevent the development of cancer cachexia induced by prostate cancer through the suppression of IL-6 in an animal model. Less
体外培养的JCA-1细胞产生了白血病抑制因子(LIF)中水平的时间依赖性增加。NFkappaB抑制剂对JCA细胞的LIF产生抑制作用。另一方面,重组LIF对前列腺癌细胞系、PC3、DU145和JCA-1细胞的生长无显著影响。JCA-1肿瘤裸鼠和PC3肿瘤裸鼠血清LIF水平分别升高,而对照组裸鼠未检测到LIF水平。同时,JCA-1荷瘤小鼠在接种后28天体重下降,而无肿瘤小鼠体重增加。体外培养的JCA-1细胞也产生IL-6。与未患肿瘤的对照组小鼠相比,JCA-1荷瘤裸鼠血清IL-6水平也显著升高,并伴有体重减轻。然后,测量前列腺癌患者血清中LIF和IL-6的水平。在大多数未经治疗的患者和内分泌治疗后进展的患者中未检测到更多水平的LIF。另一方面,与A、B、C期患者相比,未经治疗的D期患者血清IL-6水平显著升高。患者在内分泌治疗后血清IL-6水平进一步升高。血清IL-6水平较高的患者血清总蛋白和白蛋白水平、血红蛋白水平和体重指数均显著低于血清IL-6水平较低的患者。血清白细胞介素-6与血清白蛋白水平、血红蛋白水平、体重指数及生产性能状况存在显著相关。与对照组小鼠相比,NFkappaB抑制剂使JCA-1荷瘤裸鼠体重、附睾脂肪和腓肠肌重量有统计学意义的增加。治疗组小鼠红细胞压积、血清白蛋白和甘油三酯水平显著高于对照组小鼠,血清IL-6水平显著低于对照组小鼠。这些结果表明,血清IL-6可能与恶病质有关,NFkappaB抑制剂可能通过抑制IL-6在动物模型中阻止前列腺癌诱导的癌症恶病质的发展。少
项目成果
期刊论文数量(15)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice
新型核因子 κB 抑制剂在裸鼠体内抑制激素难治性前列腺癌
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:KIKUCHI E.;HORIGUCHI Y.;NAKASHIMA J;KURODA K.;OYA M.;OHIGASHI T.;TAMAHASHI N.;SHIMA Y.;UMEZAWA K.;MURAI M
- 通讯作者:MURAI M
Increased activation of CCAAT/enhancer binding protein-β correlates with the invasiveness of renal cell carcinoma.
CCAAT/增强子结合蛋白-β 的激活增加与肾细胞癌的侵袭性相关。
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:Oya;M.;Horiguchi;A.;Mizuno;M.;Marumo;K.;Murai;M.
- 通讯作者:M.
Inhibition of MKP-1 expression potentiates JNK related apoptosis in renal cancer cells
- DOI:10.1097/01.ju.0000124990.37563.00
- 发表时间:2004-08-01
- 期刊:
- 影响因子:6.6
- 作者:Mizuno, R;Oya, M;Murai, M
- 通讯作者:Murai, M
Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells
- DOI:10.1002/pros.20117
- 发表时间:2005-01-01
- 期刊:
- 影响因子:2.8
- 作者:Ohigashi, T;Mizuno, R;Murai, M
- 通讯作者:Murai, M
Enhancement of diethylstilbestrol induced cytotoxicity by bcl-2 antisense oligodeoxynucleotides and a glutathione depletor for prostate cancer
bcl-2 反义寡脱氧核苷酸和谷胱甘肽消耗剂增强己烯雌酚诱导的前列腺癌细胞毒性
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:KIKUCHI E.;NAKASHIMA J.;HORIGUCHI Y.;OYA M.;OHIGASHI T.;MURAI M
- 通讯作者:MURAI M
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
NAKASHIMA Jun其他文献
NAKASHIMA Jun的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('NAKASHIMA Jun', 18)}}的其他基金
Treatment strategies of urological cancers through the regulation of inflammatory immune response by novel NFkappaB inhibitors
通过新型 NFkappaB 抑制剂调节炎症免疫反应治疗泌尿系癌症
- 批准号:
25462502 - 财政年份:2013
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Therapeutic strategy targeting NFκB-IL6 pathway against progression and paraneoplastic syndrome in prostate cancer
针对前列腺癌进展和副肿瘤综合征的 NFκB-IL6 通路治疗策略
- 批准号:
22591779 - 财政年份:2010
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Pathophysiological role of IL-6 and IL-8 in the progression of prostate cancer and cachexia
IL-6 和 IL-8 在前列腺癌和恶病质进展中的病理生理作用
- 批准号:
10671494 - 财政年份:1998
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
LiF-MxOy/C协同型正极材料的空间限域设计及高效储锂机制研究
- 批准号:JCZRQN202500977
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
男性22q1染色体易位致LIF基因失活诱发弱精症的机制研究
- 批准号:
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
磺酸化水凝胶负载LIF因子及高分化hUCMSCs修复子宫内膜损伤的作
用和机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于LIF/LIFR轴介导的磷酸化及泛素化“crosstalk”调控影响SOX9稳定性在PADC吉西他滨耐药中的作用机制研究
- 批准号:2024Y9129
- 批准年份:2024
- 资助金额:15.0 万元
- 项目类别:省市级项目
炎性CAF通过旁分泌LIF介导NCOA4可变剪接抑制子宫内膜癌铁死亡的机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
LiF基陶瓷的冷烧结机理与微波介电性能优化
- 批准号:LY23E020007
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于共振增强激光诱导击穿光谱(LIBS-LIF)技术的土壤重金属快速精准高灵敏测量方法研究
- 批准号:32301685
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
EHD1响应胚源信号LIF调控LIFR循环转运促进胚胎着床的机制研究
- 批准号:82301900
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
LIF介导的脂解与LDL/LPA/LPAR1信号激活在强直性脊柱炎病理新骨形成中的作用及机制研究
- 批准号:82372370
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
组蛋白修饰调控Lif诱导细胞非对称分裂的分子机理研究
- 批准号:32370613
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
相似海外基金
LiFナノ粒子-炭素複合化電極におけるフッ化物イオンのコンバージョン反応の実現
LiF纳米粒子-碳复合电极中氟离子转化反应的实现
- 批准号:
24K17777 - 财政年份:2024
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
白血病抑制因子 LIFの筋衛星細胞及び筋肥大への影響-筋萎縮モデルマウスでの検討-
白血病抑制因子LIF对肌肉卫星细胞和肌肉肥大的影响-肌肉萎缩模型小鼠的检查-
- 批准号:
23K16591 - 财政年份:2023
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Design a proton beamline vacuum system to hold LiF targets for neutron production
设计质子束线真空系统以容纳用于中子生产的 LiF 靶材
- 批准号:
574239-2022 - 财政年份:2022
- 资助金额:
$ 2.11万 - 项目类别:
University Undergraduate Student Research Awards
新規抗うつ薬開発を指向したアストロサイト由来LIFのストレス適応促進作用の証明
星形胶质细胞来源的 LIF 对开发新型抗抑郁药的应激适应促进作用的证明
- 批准号:
21K06806 - 财政年份:2021
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Analysis of Lif-induced blastocyst activation and implantation
Lif 诱导囊胚活化和植入分析
- 批准号:
21K16763 - 财政年份:2021
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
肝発癌および肝癌微小環境におけるLIFの生物学的意義の解析
LIF在肝癌发生及肝癌微环境中的生物学意义分析
- 批准号:
21K08005 - 财政年份:2021
- 资助金额:
$ 2.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Intranasal LIF to improve neurological recovery from perinatal hypoxia-ischema
鼻内 LIF 可改善围产期缺氧缺血的神经功能恢复
- 批准号:
10350660 - 财政年份:2020
- 资助金额:
$ 2.11万 - 项目类别:
Intranasal LIF to improve neurological recovery from perinatal hypoxia-ischema
鼻内 LIF 可改善围产期缺氧缺血的神经功能恢复
- 批准号:
9980145 - 财政年份:2020
- 资助金额:
$ 2.11万 - 项目类别:
Intranasal LIF to improve neurological recovery from perinatal hypoxia-ischema
鼻内 LIF 可改善围产期缺氧缺血的神经功能恢复
- 批准号:
10555280 - 财政年份:2020
- 资助金额:
$ 2.11万 - 项目类别:
Spatially resolved measurement of transient concentration and temperature fields using Schlieren and LIF technique
使用 Schlieren 和 LIF 技术对瞬态浓度和温度场进行空间分辨测量
- 批准号:
423448517 - 财政年份:2019
- 资助金额:
$ 2.11万 - 项目类别:
Research Grants